Tivity Health Delivers Strong Results For First Quarter 2021 With 141% Year Over Year Increase In Income From Continuing Operations

Rhea-AI Summary

Tivity Health (NASDAQ:TVTY) reported strong Q1 2021 results with revenue of $108.1 million, a significant increase in income from continuing operations to $19.9 million (up 141% year-over-year), and an Adjusted EBITDA of $41.2 million (up 36%). The company highlighted a 19% growth in in-person SilverSneakers gym visits and a 50% increase in virtual visits. Tivity updated its full-year guidance to $465 - $485 million in revenue. The recent strategic initiatives and leadership appointments aim to enhance member engagement and digital capabilities for future growth.

Positive

• Revenue increased to $108.1 million in Q1 2021
• Income from continuing operations rose to $19.9 million, a 141% increase
• Adjusted EBITDA grew to $41.2 million, reflecting a 36% year-over-year increase
• In-person SilverSneakers visits totaled 11.2 million, a 19% increase from Q4 2020
• Virtual SilverSneakers visits grew to 1.2 million, up 50% from Q4 2020
• Updated full-year revenue guidance raised to $465 - $485 million

Negative

• Revenue declined by approximately 32% compared to Q1 2020, primarily due to fewer fitness location visits
• Significant decrease in SilverSneakers revenue of $41.8 million attributed to COVID-19 impact
• Cash flows from operating activities decreased from $25.7 million in Q1 2020 to $22.6 million in Q1 2021

NASHVILLE, Tenn., May 5, 2021 /PRNewswire/ -- Tivity Health, Inc. (NASDAQ:TVTY), today announced financial results for the first quarter ended March 31, 2021.

Richard Ashworth, President and Chief Executive Officer, commented, "We delivered strong results for the first quarter of 2021, allowing us to tighten the ranges on revenue and Adjusted EBITDA guidance for the full year. We successfully expanded our SilverSneakers virtual offerings by launching a new Roku application for viewing on-demand content and are on track to deploy our omni-channel capabilities by the start of the third quarter.  These strategic initiatives combined with the continued momentum in the number of in-person visits give us optimism for the remainder of the year.  The recent additions of our new Chief Information Officer (CIO) and Chief Experience and Innovation Officer (CXIO) underline our commitment to quickly expand our member-centric engagement through a robust platform which includes digital and in-person experiences."

First Quarter Highlights

• Revenue from continuing operations was $108.1 million during the first quarter of 2021; 
• Income from continuing operations was $19.9 million, an increase of $11.7 million, or 141%, over the prior year; 
• Adjusted EBITDA from continuing operations was $41.2 million, representing an increase of $11.0 million, or 36%, compared to the prior year;
• In-person SilverSneakers gym visits totaled 11.2 million for Q1 2021, growing by 19% over the fourth quarter of 2020; 
• Virtual SilverSneakers visits accelerated, totaling 1.2 million during the quarter, a 50% increase over the fourth quarter of 2020, with 36% of virtual visit participants being new to SilverSneakers;
• The Company ended the quarter with cash on hand of $52.4 million and a leverage ratio of 2.11, as calculated under its credit agreement.  During the first quarter of 2021, the Company prepaid $63.6 million of principal and amortization of term loan debt.  The Company's next quarterly installment is not due until December 2022;
• A new comprehensive scientific study conducted by Avalere Health showed that total average healthcare expenses for SilverSneakers participants were 16% lower compared to non-participating Medicare Advantage members.

First Quarter 2021 Financial Information

Dollars in millions, except per-share data
See pages 9-13 for a reconciliation of non-GAAP financial measures.

	Three Months Ended March 31,
	2021	2020
Revenues from Continuing Operations	$108.1	$159.7
Income from Continuing Operations	$19.9	$8.3
Income from Continuing Operations Margin	18.5%	5.2%
Adjusted EBITDA from Continuing Operations	$41.2	$30.2
Adjusted EBITDA from Continuing Operations Margin	38.1%	18.9%
Diluted Earnings Per Share from Continuing Operations	$0.40	$0.17
Adjusted Diluted Earnings Per Share from Continuing Operations	$0.40	$0.25
Cash Flows from Operating Activities – former Healthcare segment (1)	$22.6	$25.7
Free Cash Flow – former Healthcare segment (1)	$19.4	$22.5

(1)	For comparability, figures for 2020 represent cash flows from the Company's former Healthcare segment.

Revenues in the first quarter of 2021 of $108.1 million decreased $51.6 million, or approximately 32%, compared to the first quarter of 2020, primarily as a result of a significant decrease in SilverSneakers revenue of $41.8 million resulting from fewer revenue-generating visits due to the COVID-19 pandemic.  Additionally, Prime Fitness revenue decreased by $10.2 million primarily due to terminations and suspensions.

The mix of SilverSneakers revenue during the first quarter of 2021 remained different from the mix during the first quarter of 2020 due to the reduction in fitness location visits resulting from the COVID-19 pandemic. Revenue from per-member-per-month fees represented 53% of the Company's SilverSneakers revenue in the first quarter of 2021, compared to 36% in the same quarter of 2020.   

Income from continuing operations for the first quarter of 2021 was $19.9 million, an increase of $11.7 million compared to the first quarter of 2020.  Adjusted EBITDA was $41.2 million for the first quarter, or 38.1% of revenues, compared to $30.2 million for the first quarter of 2020, or 18.9% of revenues.  This improvement is primarily due to the mix of per-member-per-month fees for SilverSneakers driven by a reduction in fitness location visits and related costs for SilverSneakers and Prime, and also reflects a reduction in advertising expense and employee-related expenses.

During the first quarter, the Company prepaid $63.6 million of principal amortization on its term loan debt, and net debt (total debt less cash and cash equivalents) improved to $353 million, resulting in a net leverage ratio of 2.11. The Company's next quarterly installment is not due until December 2022. 

Updated 2021 Financial Guidance

Tivity Health announced today that, based on first-quarter results and the Company's outlook for the remainder of 2021, it has updated its financial guidance as follows:

 Dollars in millions, except per-share data

	February 24, 2021 (Prior Guidance)	May 5, 2021 (Updated Guidance)
Revenues	$455 - $485	$465 - $485
Income from Continuing Operations	$70.5 - $74.3	$71.3 - $74.3
Adjusted EBITDA (1)	$150 - $155	$151 - $155
Depreciation Expense	Approximately $14	Unchanged
Interest Expense	Approximately $37, including $6 of non-cash	Unchanged
Effective Tax Rate	Approximately 25%	Unchanged
Weighted Average Diluted Shares Outstanding	50.0 million – 50.5 million	Unchanged
Earnings per Diluted Share	$1.40 - $1.49	$1.41 - $1.49
Adjusted Earnings per Diluted Share (1)	$1.47 - $1.56	$1.49 - $1.56
Cash Flows from Operating Activities	$81 - $85	Unchanged
Free Cash Flow (1)	$50 - $60	Unchanged
Capital Expenditures	$20 - $25	Unchanged

Tivity Health's detailed guidance considerations for 2021 may be found in the supplemental information posted on the Company's website at http://investors.tivityhealth.com.  

(1)	Adjusted EBITDA, adjusted earnings per diluted share, and free cash flow are non-GAAP financial measures. See pages 9-13 for a reconciliation of non-GAAP financial measures.

Conference Call

Tivity Health will hold a conference call to discuss this release today at 5:00 p.m. Eastern Time.  Investors will have the opportunity to listen to the conference call live by dialing 877-683-2218 or 647-689-5447 for international callers, and referencing code 4896873 or over the Internet by going to www.tivityhealth.com and clicking "Investors" at least 15 minutes early to register, download, and install any necessary audio software. For those who cannot listen to the live broadcast, a telephonic replay will be available for one week at 800-585-8367 or 416-621-4642 for international callers, code 4896873, and the replay will also be available on the Company's web site for the next 7 months.

About Tivity Health

Tivity Health^® Inc. (Nasdaq: TVTY) is a leading provider of healthy life-changing solutions, including SilverSneakers^®, Prime^® Fitness, WholeHealth Living^® and Wisely Well™.  We are focused on becoming the modern destination for healthy living.  We will expand beyond fitness by establishing an engagement platform that enables personalized member interaction with all of our offerings, and we will partner with other payors and service providers to aggregate services to seniors under the SilverSneakers umbrella.  The continued development of our suite of digital offerings will enable a more tailored, interactive, and impactful experience across a variety of areas, including fitness, social connection, community involvement, volunteering, and enrichment.  Learn more at www.tivityhealth.com.

Non-GAAP Financial Measures

This press release contains certain non-GAAP financial measures. Reconciliations of certain of these non-GAAP measures to the comparable GAAP measures are included on pages 9-13.   

Cautionary Statement Regarding Forward-Looking Statements

This press release contains certain statements that are "forward-looking" statements within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are based upon current expectations and include all statements that are not historical statements of fact and those regarding the intent, belief or expectations, including, without limitation, statements that are accompanied by words such as "will," "expect," "outlook," "anticipate," "intend," "plan," "believe," "seek," "see," "would," "target," or other similar words, phrases or expressions and variations or negatives of these words. These forward-looking statements include, but are not limited to, the Company's statements regarding its future financial performance. Readers of this press release should understand that these statements are not guarantees of performance or results. Many risks and uncertainties could affect actual results and cause them to vary materially from the forward-looking statements.

These risks and uncertainties include, among other things: impacts from the COVID-19 pandemic (including the response of governmental authorities to combat and contain the pandemic, the closure of fitness centers in the Company's national network (or operational restrictions imposed on such fitness centers), reclosures and potential additional reclosures as a result of surges in positive COVID-19 cases) on the Company's business, operations or liquidity; the risks associated with changes in macroeconomic conditions (including the impacts of any recession or changes in consumer spending resulting from the COVID-19 pandemic), widespread epidemics, pandemics (such as the current COVID-19 pandemic) or other outbreaks of disease, geopolitical turmoil, and the continuing threat of domestic or international terrorism; the Company's ability to collect accounts receivable from its customers and amounts due under its sublease agreements; the market's acceptance of the Company's new products and services; the Company's ability to develop and implement effective strategies and to anticipate and respond to strategic changes, opportunities, and emerging trends in the Company's industry and/or business, as well as to accurately forecast the related impact on the Company's revenues and earnings; the impact of any impairment of the Company's goodwill, intangible assets, or other long-term assets; the Company's ability to attract, hire, or retain key personnel or other qualified employees and to control labor costs; the effectiveness of the reorganization of the Company's business and the Company's ability to realize the anticipated benefits; the Company's ability to effectively compete against other entities, whose financial, research, staff, and marketing resources may exceed its resources; the impact of legal proceedings involving the Company and/or its subsidiaries, products, or services, including any claims related to intellectual property rights, as well as our ability to maintain insurance coverage with respect to such legal proceedings and claims on terms that would be favorable to us; the impact of severe or adverse weather conditions, the current COVID-19 pandemic, and the potential emergence of additional health pandemics or infectious disease outbreaks on member participation in the Company's programs; the risks associated with deriving a significant concentration of revenues from a limited number of the Company's customers, many of whom are health plans; the Company's ability and/or the ability of its customers to enroll participants and to accurately forecast their level of enrollment and participation in the Company's programs in a manner and within the timeframe anticipated by the Company; the Company's ability to sign, renew and/or maintain contracts with its customers and/or the Company's fitness partner locations under existing terms or to restructure these contracts on terms that would not have a material negative impact on the Company's results of operations; the ability of the Company's health plan customers to maintain the number of covered lives enrolled in those health plans during the terms of the Company's agreements; the Company's ability to add and/or retain active subscribers in its Prime Fitness program; the impact of any changes in tax rates, enactment of new tax laws, revisions of tax regulations or any claims or litigation with taxing authorities; the impact of a reduction in Medicare Advantage health plan reimbursement rates or changes in plan design; the impact of any new or proposed legislation, regulations and interpretations relating to Medicare, Medicare Advantage, Medicare Supplement, and privacy and security laws; the impact of healthcare reform on the Company's business; the risks associated with potential failures of the Company's information systems or those of our third-party vendors, including as a result of telecommuting issues associated with the Company's employees working remotely, which may include a failure to execute on policies and processes in a work-from-home or remote model; the risks associated with data privacy or security breaches, computer hacking, network penetration and other illegal intrusions of the Company's information systems or those of third-party vendors or other service providers, including those risks that result from the increase in personnel working remotely, which may result in unauthorized access by third parties, loss, misappropriation, disclosure or corruption of customer, employee or the Company's information, or other data subject to privacy laws and may lead to a disruption in the Company's business, costs to modify, enhance, or remediate its cybersecurity measures, enforcement actions, fines or litigation against the Company, or damage to its business reputation; the risks associated with changes to traditional office-centered business processes and/or conducting operations out of the office in a work-from-home or remote model by us or our third party vendors during adverse situations (e.g., during a crisis, disaster, or pandemic), which may result in additional costs and/or may negatively impact productivity and cause other disruptions to the Company's business; the Company's ability to enforce its intellectual property rights; the risk that the Company's indebtedness may limit the Company's ability to adapt to changes in the economy or market conditions, expose the Company to interest rate risk for the variable rate indebtedness and require a substantial portion of cash flows from operations to be dedicated to the payment of indebtedness; the Company's ability to service its debt, make principal and interest payments as those payments become due, and remain in compliance with its debt covenants; the Company's ability to obtain adequate financing to provide the capital that may be necessary to support its current or future operations; counterparty risk associated with the Company's interest rate swap agreements; and other risks detailed in the Company's filings with the Securities and Exchange Commission.

For additional information about factors that could cause actual results to differ materially from those described in the forward-looking statements, please refer to the Company's filings with the SEC. Except as required by law, the Company undertakes no obligation to update any such forward-looking statements to reflect new information, subsequent events or circumstances.

 

TIVITY HEALTH, INC. CONSOLIDATED BALANCE SHEETS (In thousands, except share and per share data) (Unaudited)
		March 31, 2021				December 31, 2020
Current assets:
Cash and cash equivalents		$	52,428			$	100,385
Accounts receivable, net			44,959				25,981
Prepaid expenses			4,154				5,556
Income taxes receivable			779				10,996
Other current assets			19,586				11,336
Total current assets			121,906				154,254
Property and equipment, net of accumulated depreciation of    $40,713 and $38,188 respectively			19,981				20,959
Right-of-use assets			16,288				18,139
Long-term deferred tax asset			1,186				3,601
Intangible assets, net			29,049				29,049
Goodwill, net			334,680				334,680
Other assets			16,808				18,301
Total assets		$	539,898			$	578,983
Current liabilities:
Accounts payable		$	18,400			$	19,741
Accrued salaries and benefits			5,264				8,949
Accrued liabilities			31,395				18,424
Deferred revenue			4,351				4,460
Current portion of long-term debt			7,456				7,456
Current portion of lease liabilities			8,064				8,052
Current portion of other long-term liabilities			14,195				14,753
Total current liabilities			89,125				81,835
Long-term debt			397,750				459,250
Long-term lease liabilities			9,460				11,494
Other long-term liabilities			17,309				22,748
Commitments and contingent liabilities
Stockholders' equity:
Preferred stock $.001 par value, 5,000,000 shares authorized,    none outstanding			—				—
Common Stock $.001 par value, 120,000,000 shares authorized,    49,246,281 and 48,983,735 shares outstanding, respectively			49				49
Additional paid-in capital			513,923				513,263
Accumulated deficit			(444,949)				(464,085)
Treasury stock, at cost, 2,254,953 shares in treasury			(28,182)				(28,182)
Accumulated other comprehensive loss			(14,587)				(17,389)
Total stockholders' equity			26,254				3,656
Total liabilities and stockholders' equity		$	539,898			$	578,983

 

TIVITY HEALTH, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except earnings per share data) (Unaudited)
		Three Months Ended March 31,
		2021				2020
Revenues		$	108,085			$	159,692
Cost of revenue (exclusive of depreciation of $2,531 and $1,831, respectively, included below)			57,285				115,148
Marketing expense			1,231				7,299
Selling, general and administrative expenses			9,696				12,052
Depreciation expense			2,683				2,030
Restructuring and related charges			—				482
Operating income			37,190				22,681
Interest expense			10,756				11,270
Other (income) expense, net			(1,130)				—
Total non-operating expense, net			9,626				11,270
Income before income taxes			27,564				11,411
Income tax expense			7,620				3,136
Income from continuing operations		$	19,944			$	8,275
Loss from discontinued operations, net of income tax benefit of $277    and $18,282, respectively			(808)				(206,381)
Net income (loss)		$	19,136			$	(198,106)
Earnings (loss) per share - basic:
Continuing operations		$	0.41			$	0.17
Discontinued operations		$	(0.02)			$	(4.25)
Net income (loss)		$	0.39			$	(4.08)
Earnings (loss) per share - diluted:
Continuing operations		$	0.40			$	0.17
Discontinued operations		$	(0.02)			$	(4.22)
Net income (loss)		$	0.38			$	(4.05)
Comprehensive income (loss)		$	21,938			$	(217,935)
Weighted average common shares and equivalents:
Basic			49,222				48,613
Diluted			50,340				48,855

 

TIVITY HEALTH, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands) (Unaudited)
		Three Months Ended March 31,
		2021				2020
Cash flows from operating activities:
Income from continuing operations		$	19,944			$	8,275
Loss from discontinued operations			(808)				(206,381)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization			2,683				14,763
Amortization and write-off of deferred loan costs			1,183				1,212
Amortization and write-off of debt discount			1,077				1,095
Share-based employee compensation expense			2,998				824
Gain on derivatives			(1,130)				—
Impairment of goodwill and intangible assets of discontinued operation			—				199,500
Deferred income taxes			1,454				(16,031)
(Increase) decrease in accounts receivable, net			(18,978)				16,665
Decrease in income taxes receivable			10,217				—
Decrease in inventory			—				4,057
Decrease in other current assets			529				4,746
(Decrease) increase in accounts payable			(42)				12,612
Decrease in accrued salaries and benefits			(3,685)				(4,852)
Increase in other current liabilities			5,594				5,501
(Decrease) increase in deferred revenue			(109)				3,247
Other			1,691				1,790
Net cash flows provided by operating activities		$	22,618			$	47,023
Cash flows from investing activities:
Acquisition of property and equipment		$	(1,561)			$	(4,875)
Settlement on derivatives not designated as hedges			(1,633)				—
Net cash flows used in investing activities		$	(3,194)			$	(4,875)
Cash flows from financing activities:
Proceeds from issuance of long-term debt		$	—			$	160,325
Payments of long-term debt			(63,600)				(123,000)
Payments related to tax withholding for share-based compensation			(2,502)				(2,795)
Exercise of stock options			164				601
Change in cash overdraft and other			(1,443)				3,269
Net cash flows (used in) provided by financing activities		$	(67,381)			$	38,400
Net (decrease) increase in cash and cash equivalents		$	(47,957)			$	80,548
Cash and cash equivalents, beginning of period		$	100,385			$	2,486
Cash and cash equivalents, end of period		$	52,428			$	83,034

 

TIVITY HEALTH, INC.  RECONCILIATION OF NON-GAAP MEASURES TO GAAP MEASURES (Unaudited)
Reconciliation of Income from Continuing Operations, GAAP Basis to Adjusted EBITDA from Continuing Operations, Non-GAAP Basis (in thousands)
				Three Months Ended March 31, 2021			% of Revenue		Three Months Ended March 31, 2020		% of Revenue
Income from continuing operations, GAAP basis			$	19,944			18.5%	$	8,275		5.2%
Depreciation expense				2,683					2,030
Interest expense				10,756					11,270
Income tax expense				7,620					3,136
EBITDA from continuing operations, non-GAAP basis (1)			$	41,003				$	24,711
Acquisition, integration, project, and CEO transition costs (2)				1,321					5,049
Restructuring charges (3)				—					482
Other (income)/expense (4)				(1,130)					—
Adjusted EBITDA from continuing operations, non-GAAP basis (5)			$	41,194			38.1%	$	30,242		18.9%

(1)	EBITDA from continuing operations is a non-GAAP financial measure.  The Company believes it is useful to investors to provide disclosures of its operating results and guidance on the same basis as that used by management.  You should not consider EBITDA from continuing operations in isolation or as a substitute for income from continuing operations determined in accordance with U.S. GAAP.
(2)	Acquisition, integration, project, and CEO transition costs consist of pre-tax charges of $1,321 and $5,049 for the three months ended March 31, 2021 and 2020, respectively, primarily incurred in connection with the acquisition and integration of Nutrisystem and with the termination of the Company's former CEO in February 2020 and the hiring of a new CEO in June 2020.
(3)	Restructuring charges consist of pre-tax charges of $482 for the three months ended March 31, 2020, primarily related to a restructuring of corporate support infrastructure and of executive leadership.
(4)	Other (income)/expense consists of pre-tax income of $1,130 related to certain interest rate swap agreements that do not qualify for hedge accounting treatment ("de-designated swaps") and require changes in fair value to be recognized each period in current earnings.
(5)	Adjusted EBITDA from continuing operations is a non-GAAP financial measure.  The Company excludes acquisition, integration, project, and CEO transition costs, restructuring charges, and other (income)/expense from this measure because of its comparability to the Company's historical operating results.  The Company updated its definition of adjusted EBITDA during the first quarter of 2021 to exclude other (income)/expense related to de-designated swaps. The Company considers such (income)/expense to be outside the performance of its ongoing core business operations and believes that presenting Adjusted EBITDA excluding other (income)/expense provides increased transparency as to the operating costs of its current business performance. The Company did not revise the prior period's Adjusted EBITDA amounts because there were no costs similar in nature to these items.  The Company believes it is useful to investors to provide disclosures of its operating results on the same basis as that used by management.  You should not consider Adjusted EBITDA from continuing operations in isolation or as a substitute for income from continuing operations determined in accordance with U.S. GAAP.  Additionally, because Adjusted EBITDA from continuing operations may be defined differently by other companies in the Company's industry, the non-GAAP financial measure presented here may not be comparable to similarly titled measures of other companies.

 

Reconciliation of Income from Continuing Operations Guidance, GAAP Basis to Adjusted EBITDA from Continuing Operations Guidance, Non-GAAP Basis (in millions)
				Year Ending December 31, 2021
Income from continuing operations guidance, GAAP basis				$71.3 - $74.3
Depreciation expense				14
Interest expense				37
Income tax expense				23.8 – 24.8
EBITDA from continuing operations, non-GAAP basis (6)				$146 - $150
Integration, project, and CEO transition costs (7)				5
Adjusted EBITDA from continuing operations guidance, non-GAAP basis (8)				$151 - $155

(6)	EBITDA from continuing operations guidance is a non-GAAP financial measure.  The Company believes it is useful to investors to provide disclosures of its operating results and guidance on the same basis as that used by management.  You should not consider EBITDA from continuing operations guidance in isolation or as a substitute for income from continuing operations determined in accordance with U.S. GAAP.  Figures may not add due to rounding.
(7)	Integration, project, and CEO transition costs primarily relate to strategic projects and the Company's transition to a new CEO during 2020.
(8)	Adjusted EBITDA from continuing operations guidance is a non-GAAP financial measure.  The Company excludes integration, project, and CEO transition costs from this measure because of its comparability to the Company's historical operating results.  The Company believes it is useful to investors to provide disclosures of its operating results and guidance on the same basis as that used by management.  You should not consider Adjusted EBITDA from continuing operations guidance in isolation or as a substitute for income from continuing operations guidance determined in accordance with U.S. GAAP.  Additionally, because Adjusted EBITDA from continuing operations guidance may be defined differently by other companies in the Company's industry, the non-GAAP financial measure presented here may not be comparable to similarly titled measures of other companies.

 

Reconciliation of Net Cash Flows Provided by Operations, GAAP Basis to Free Cash Flow, Non-GAAP Basis (in thousands)
				Three Months Ended March 31, 2021				Three Months Ended March 31, 2020
Net cash flows provided by operations, GAAP basis			$	22,618			$	47,023
Acquisition of property and equipment				(1,561)				(4,875)
Settlement on derivatives not designated as hedges				(1,633)				—
Free cash flow, non-GAAP basis (9)			$	19,424			$	42,148

(9)

Free cash flow is a non-GAAP financial measure and is defined by the Company as net cash flows provided by operating activities less acquisition of property and equipment and settlement on derivatives not designated as hedges.  The Company updated its definition of free cash flow during the fourth quarter of 2020 to exclude settlement on derivatives not designated as hedges. The Company considers these costs to be a reduction of cash available for other uses and believes that presenting free cash flow excluding settlement on derivatives provides increased transparency. The Company did not revise prior periods' free cash flow because there were no costs similar in nature to this item. The Company believes free cash flow is a useful measure of performance and an indication of the strength of the Company and its ability to generate cash.  The Company believes it is useful to investors to provide disclosures of its results on the same basis as that used by management.  You should not consider free cash flow in isolation or as a substitute for net cash flows provided by operating activities determined in accordance with U.S. GAAP. Additionally, because free cash flow may be defined differently by other companies in the Company's industry, the non-GAAP financial measure presented here may not be comparable to similarly titled measures of other companies.

 

Reconciliation of Net Cash Flows Provided by Operations from Former Healthcare Segment, GAAP Basis to Free Cash Flow from Former Healthcare Segment, Non-GAAP Basis (in thousands)
				Three Months Ended March 31, 2021				Three Months Ended March 31, 2020
Net cash flows provided by operations from former Healthcare segment, GAAP basis			$	22,618			$	25,735
Acquisition of property and equipment				(1,561)				(3,193)
Settlement on derivatives not designated as hedges				(1,633)				—
Free cash flow from former Healthcare segment, non-GAAP basis (10)			$	19,424			$	22,542

(10)

Free cash flow from former Healthcare segment is a non-GAAP financial measure and is defined by the Company as net cash flows provided by operating activities less acquisition of property and equipment and settlement on derivatives not designated as hedges.  The Company updated its definition of free cash flow during the fourth quarter of 2020 to exclude settlement on derivatives not designated as hedges. The Company considers these costs to be a reduction of cash available for other uses and believes that presenting free cash flow excluding settlement on derivatives provides increased transparency. The Company did not revise prior periods' free cash flow because there were no costs similar in nature to this item. The Company believes free cash flow is a useful measure of performance and an indication of the strength of the Company and its ability to generate cash.  The Company believes it is useful to investors to provide disclosures of its results on the same basis as that used by management.  You should not consider free cash flow from former Healthcare segment in isolation or as a substitute for net cash flows provided by operating activities determined in accordance with U.S. GAAP. Additionally, because free cash flow may be defined differently by other companies in the Company's industry, the non-GAAP financial measure presented here may not be comparable to similarly titled measures of other companies.

 

Reconciliation of Net Cash Flows Provided by Operations Guidance, GAAP Basis to Free Cash Flow Guidance, Non-GAAP Basis (in millions)
				Year Ending December 31, 2021
Net cash flows provided by operations guidance, GAAP basis			$	81 - 85
Acquisition of property and equipment guidance				(25 - 20)
Settlement on derivatives not designated as hedges guidance				(6 - 5)
Free cash flow guidance, non-GAAP basis (11)			$	50 - 60

(11)

Free cash flow guidance is a non-GAAP financial measure and is defined by the Company as net cash flows provided by operating activities less acquisition of property and equipment and settlement on derivatives not designated as hedges.  The Company believes free cash flow is a useful measure of performance and an indication of the strength of the Company and its ability to generate cash.  The Company believes it is useful to investors to provide disclosures of its results and guidance on the same basis as that used by management.  You should not consider free cash flow guidance in isolation or as a substitute for net cash flows provided by operating activities guidance determined in accordance with U.S. GAAP. Additionally, because free cash flow may be defined differently by other companies in the Company's industry, the non-GAAP financial measure presented here may not be comparable to similarly titled measures of other companies.

 

Reconciliation of Earnings Per Share ("EPS") from Continuing Operations, GAAP Basis to Adjusted EPS from Continuing Operations, Non-GAAP Basis (footnote amounts in thousands)
			Three Months Ended March 31, 2021			Three Months Ended March 31, 2020
EPS from continuing operations, GAAP basis		$	0.40		$	0.17
Net loss per share attributable to acquisition, integration, project, CEO transition, and restructuring costs (12)			0.02			0.08
Net income per share attributable to other (income)/expense (13)			(0.02)			—
Adjusted EPS from continuing operations, non-GAAP basis (14)		$	0.40		$	0.25

(12)	Net loss attributable to acquisition, integration, project, CEO transition, and restructuring costs consists of pre-tax charges of $1,321 and $5,531 for the three months ended March 31, 2021 and 2020, respectively.  These costs primarily related to the acquisition and integration of Nutrisystem, the termination of our former CEO in February 2020 and hiring of our new CEO in June 2020, and restructuring activities as described in Note 3 above.  The tax rate applied to these charges was 25%, which represented the combined estimated U.S. federal and state statutory tax rate.
(13)	Net income attributable to other (income)/expense consists of pre-tax income of $1,130 for the three months ended March 31, 2021 related to de-designated swaps, as described in Note 4 above.  The tax rate applied to this income was 25%, which represented the combined estimated U.S. federal and state statutory tax rate
(14)	Adjusted EPS from continuing operations is a non-GAAP financial measure.  The Company excludes net (income) loss per share attributable to acquisition, integration, CEO transition, and restructuring costs and other (income)/expense from this measure because of its comparability to the Company's historical operating results.  The Company believes it is useful to investors to provide disclosures of its operating results on the same basis as that used by management.  You should not consider adjusted EPS from continuing operations in isolation or as a substitute for EPS from continuing operations determined in accordance with U.S. GAAP.  Additionally, because adjusted EPS from continuing operations may be defined differently by other companies in the Company's industry, the non-GAAP financial measures presented here may not be comparable to similarly titled measures of other companies.

 

Reconciliation of EPS from Continuing Operations Guidance, GAAP Basis to Adjusted EPS from Continuing Operations Guidance, Non-GAAP Basis (footnote amounts in thousands)
			Year Ending December 31, 2021
EPS from continuing operations guidance, GAAP basis			$1.41 - $1.49
Net loss per share attributable to restructuring, integration project, and CEO transition costs guidance (15)			0.07
Adjusted EPS from continuing operations guidance, non-GAAP basis (16)		$	$1.49 – 1.56

(15)

Net loss per share attributable to restructuring, integration, project, and CEO transition costs guidance consists of pre-tax charges of $5,000 for the year ending December 31, 2021.  These costs primarily relate to strategic projects, the Company's transition to a new CEO during 2020, and restructuring activities.  The tax rate applied to these charges was 25%, which represents the combined estimated U.S. federal and state statutory tax rate.

(16)

Adjusted EPS from continuing operations guidance is a non-GAAP financial measure.  The Company excludes net loss attributable to restructuring, project, and CEO transition costs from this measure because of its comparability to the Company's historical operating results.  The Company believes it is useful to investors to provide disclosures of its operating results and guidance on the same basis as that used by management.  You should not consider adjusted EPS from continuing operations guidance in isolation or as a substitute for EPS from continuing operations guidance determined in accordance with U.S. GAAP.  Additionally, because adjusted EPS from continuing operations guidance may be defined differently by other companies in the Company's industry, the non-GAAP financial measures presented here may not be comparable to similarly titled measures of other companies.  Figures may not add due to rounding.

 

Reconciliation of Total Debt, GAAP Basis to Net Debt, Non-GAAP Basis (in thousands)
				March 31, 2021				March 31, 2020
Total debt, GAAP basis			$	405,206			$	1,087,599
Cash and cash equivalents				(52,428)				(83,034)
Net debt, non-GAAP basis (17)			$	352,778			$	1,004,565

(17)

Net debt is a non-GAAP financial measure.  The Company excludes cash and cash equivalents from this measure and believes that net debt is an important measure to monitor its leverage and evaluate the balance sheet.  The Company believes it is useful to investors to provide disclosures of its financial position on the same basis as that used by management.  You should not consider net debt in isolation or as a substitute for total debt determined in accordance with U.S. GAAP.  Additionally, because net debt may be defined differently by other companies in the Company's industry, the non-GAAP financial measures presented here may not be comparable to similarly titled measures of other companies.

 

View original content:http://www.prnewswire.com/news-releases/tivity-health-delivers-strong-results-for-first-quarter-2021-with-141-year-over-year-increase-in-income-from-continuing-operations-301284908.html

SOURCE Tivity Health, Inc.

FAQ

What were Tivity Health's Q1 2021 revenue results?

Tivity Health reported revenue of $108.1 million for Q1 2021.

How did Tivity Health's income from continuing operations change in Q1 2021?

Income from continuing operations increased to $19.9 million, a 141% rise compared to Q1 2020.

What is Tivity Health's updated financial guidance for 2021?

The company raised its revenue guidance to $465 - $485 million for 2021.

What was the growth in SilverSneakers visits reported in Q1 2021?

In-person SilverSneakers visits grew by 19% to 11.2 million, and virtual visits increased by 50% to 1.2 million.

What key initiatives did Tivity Health implement in Q1 2021?

Tivity Health expanded its SilverSneakers virtual offerings and is set to deploy omni-channel capabilities.